Huong Nguyen
Pediatric Endocrinology · Fresno, CANPI 1255471975
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 233 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,368, 5.9 times the $233 reported in 2019.
Across 233 payments — averaging $22.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$615
- AstraZeneca$530
- Ascendis Pharma Endocrinology Inc$505
- Lilly USA, LLC$404
- Sanofi-aventis U.S. LLC$266
- Tolmar, Inc.$238
- plus $3K from 27 others
What the payments were for
- Food & beverage$5,12799%
- Education$421%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 37 | $615 |
| AstraZeneca | 17 | $530 |
| Ascendis Pharma Endocrinology Inc | 19 | $505 |
| Lilly USA, LLC | 24 | $404 |
| Sanofi-aventis U.S. LLC | 11 | $266 |
| Tolmar, Inc. | 11 | $238 |
| Mannkind Corporation | 7 | $215 |
| Tolmar Pharmaceuticals, Inc. | 10 | $210 |
| Pfizer | 9 | $184 |
| Dexcom, Inc. | 10 | $175 |
| Novo Nordisk | 8 | $174 |
| Kyowa Kirin, Inc. | 7 | $162 |
| Insulet Corporation | 8 | $152 |
| Amgen(2 entities) | 4 | $151 |
| Biomarin Pharmaceutical Inc. | 6 | $147 |
| Xeris Pharmaceuticals, Inc. | 7 | $135 |
| Ultragenyx Pharmaceutical Inc. | 2 | $124 |
| Soleno Therapeutics, Inc. | 4 | $117 |
| Azurity Pharmaceuticals, Inc. | 5 | $95 |
| Tandem Diabetes Care, Inc. | 3 | $84 |
| Abbott | 4 | $68 |
| Neurocrine Biosciences, Inc. | 3 | $66 |
| Medtronic | 3 | $64 |
| Ferring Pharmaceuticals Inc. | 3 | $55 |
| Cranial Technologies, Inc | 2 | $39 |
| Seqirus USA Inc | 2 | $33 |
| Sequel Med Tech, LLC | 1 | $33 |
| Rhythm Pharmaceuticals, Inc. | 1 | $29 |
| Bigfoot Biomedical Inc | 1 | $29 |
| Vistapharm, Inc. | 1 | $23 |
| Dermira, Inc. | 1 | $20 |
| Medline Industries LP | 1 | $16 |
| Cequr Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,169 in reported general payments places this provider in the 75th percentile of 168 pediatric endocrinology providers in California.
Other pediatric endocrinology in Fresno
- Gnanagurdasan PrakasamSacramento$805K
- Swati ElchuriVentura$210K
- Karen KleinSan Diego$195K
- Francine KaufmanLos Angeles$184K
- Lynda PolgreenOrange$167K
- Kevin KaisermanWest Covina$150K
- Amrit BhangooLong Beach$140K
- Mitchell GeffnerLos Angeles$129K
- Stephen GitelmanSan Francisco$105K
- David MaahsStanford$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.